Payment overview · 2025
General Payments
$5,579.76
92 reported records · 20 companies
Healthcare provider profile · identity verified
Ronald G Beebe, MD
Allopathic & Osteopathic Physicians|Allergy & Immunology · GAINESVILLE, GA · NPI 1760445852
Verified facts
What the public records show
CMS Open Payments records show Ronald G Beebe, MD received $5,579.76 in general payments during 2025 across 92 reported records.
AstraZeneca Pharmaceuticals LP accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cuvitru, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xolair by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Cuvitru by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $3,728.08 | 66.8% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $374.19 | 6.7% | 14 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $230.95 | 4.1% | 9 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $212.05 | 3.8% | 9 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $169.63 | 3.0% | 7 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $142.81 | 2.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $139.35 | 2.5% | 11 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $94.99 | 1.7% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.62 | 1.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.40 | 1.2% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $65.25 | 1.2% | 3 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $49.80 | 0.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.22 | 0.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.95 | 0.8% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $30.00 | 0.5% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $25.48 | 0.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.52 | 0.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.03 | 0.4% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.45 | 0.3% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $18.99 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,450.00 | 4 |
| Food and Beverage | $1,995.77 | 85 |
| Education | $119.99 | 2 |
| Travel and Lodging | $14.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $3,736.24 | 12 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $492.34 | 16 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $212.05 | 9 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $158.68 | 6 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $142.81 | 7 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $122.21 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $94.00 | 8 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $72.27 | 3 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $65.40 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $65.40 | 3 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $49.80 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.35 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Sajazir Normalized: sajazir |
Drug | Cycle Pharmaceuticals Inc | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $9.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CUVITRU cuvitru |
2025 | Cuvitru | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 291 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
291 | 55 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 724 | 195 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 291 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 87 |
| Breo Ellipta | Fluticasone/Vilanterol | 185 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 52 |
| Prednisone | Prednisone | 160 | 119 |
| Eliquis | Apixaban | 136 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 130 | 35 |
| Ipratropium Bromide | Ipratropium Bromide | 127 | 50 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 118 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 97 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 41 |
| Furosemide | Furosemide | 70 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 59 | 12 |
| Omeprazole | Omeprazole | 58 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 57 | 16 |
| Trazodone Hcl | Trazodone Hcl | 55 | 11 |
| Doxepin Hcl | Doxepin Hcl | 52 | 13 |
| Gabapentin | Gabapentin | 51 | 14 |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Sertraline Hcl | Sertraline Hcl | 49 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | 14 |
| Cefdinir | Cefdinir | 45 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | 11 |
| Lisinopril | Lisinopril | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 33 |
| Dupixent Syringe | Dupilumab | 37 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | 12 |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Losartan Potassium | Losartan Potassium | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Xolair | Omalizumab | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dupixent Pen | Dupilumab | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,579.76 · 92 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Andembry, CUTAQUIG, CUVITRU, DAWNZERA, DUPIXENT, FASENRA, Haegarda, Hizentra, NEFFY, NEMLUVIO, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORLADEYO, Ohtuvayre, PANZYGA, RUCONEST, Rhapsido, Sajazir, TAKHZYRO, TEZSPIRE, TRELEGY ELLIPTA, Xembify, Xhance, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cuvitru play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error